Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | TK1 | P04183 | 1/20 | 0.35 |
| ▸ | TK2 | O00142 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21178041 | 0.99 | LMNA (0.45) | LMNASMN1; SMN2MAPTESR1NT5E | |
| SCHEMBL22801189 | 0.96 | LMNA (0.47) | LMNASMN1; SMN2MAPTESR1NT5E | |
| SCHEMBL22801215 | 0.91 | LMNA (0.45) | LMNASMN1; SMN2MAPTESR1NT5E | |
| SCHEMBL22801218 | 0.89 | LMNA (0.43) | LMNASMN1; SMN2MAPTESR1NT5E | |
| SCHEMBL21178264 | 0.85 | LMNA (0.45) | LMNASMN1; SMN2MAPTESR1NT5E | |
| SCHEMBL22801236 | 0.85 | LMNA (0.47) | LMNASMN1; SMN2MAPTESR1DHFR | |
| SCHEMBL21178057 | 0.84 | LMNA (0.45) | LMNASMN1; SMN2MAPTESR1TYMS | |
| SCHEMBL22801216 | 0.84 | LMNA (0.47) | LMNASMN1; SMN2MAPTESR1NT5E | |
| SCHEMBL22801246 | 0.83 | LMNA (0.46) | LMNASMN1; SMN2MAPTESR1NT5E | |
| SCHEMBL21178012 | 0.83 | LMNA (0.46) | LMNASMN1; SMN2MAPTESR1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110311-B2 | Cyclic deoxyribonucleotide compounds | NUCORION PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20220298199-A1 | CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS | NUCORION PHARMACEUTICALS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-11427550-B2 | 5-fluorouracil compounds | NUCORION PHARMACEUTICALS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3999519-A1 | CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS | NUCORION PHARMACEUTICALS, INC. (US) | 2022-05-25 | — | — | EP | disclosed |
| WO-2021011692-A1 | CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS | NUCORION PHARMACEUTICALS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20200399227-A1 | 5-FLUOROURACIL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298199-A1 | CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS | DPYD, TYMP, TYMS | LMNA 1892/4885SMN1; SMN2 2792/4885MAPT 4597/4885 |
| US-20200399227-A1 | 5-FLUOROURACIL COMPOUNDS | DPYD, DHFR, FAU | LMNA 1225/4885SMN1; SMN2 1144/4885MAPT 3566/4885 |
| US-12110311-B2 | Cyclic deoxyribonucleotide compounds | DPYD, TYMP, TYMS | LMNA 1892/4885SMN1; SMN2 2792/4885MAPT 4597/4885 |
| US-11427550-B2 | 5-fluorouracil compounds | DPYD, DHFR, MTHFD1 | LMNA 1038/4885SMN1; SMN2 1251/4885MAPT 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.